Phase 2 trial of sustained-release fampridine in chronic spinal cord injury

D. D. Cardenas, J. Ditunno, V. Graziani, A. B. Jackson, D. Lammertse, P. Potter, M. Sipski, R. Cohen, A. R. Blight

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Study design: Double-blind, randomized, placebo-controlled, parallel-group clinical trial. Objective: Assess safety and efficacy of sustained-release fampridine in subjects with chronic spinal cord injury. Setting: A total of 11 academic rehabilitation research centers in the United States. Methods: A total of 91 subjects with motor-incomplete spinal cord injury (SCI), randomized to three arms: fampridine, sustained release, 25 mg b.i.d. (Group I), 40 mg b.i.d. (Group II), and placebo (Group III) for 8 weeks. Outcome measures: Patient diary questionnaire, Ashworth score, American Spinal Cord Injury Association International Standards, International Index of Erectile Function, bladder and bowel management questionnaires, and Clinician and Subject Global Impressions (Clinician Global Impression of change, Subject Global Impression (SGI)). Safety was evaluated from adverse events, physical examinations, vital signs, electrocardiograms, and laboratory tests. Results: In total, 78% of the subjects completed the study. More (13/30) discontinued from Group II than Group I (4/30) and Group III (3/31). The most frequent adverse events across groups were hypertonia, generalized spasm, insomnia, dizziness, asthenia, pain, constipation, and headache. One subject in Group II experienced a seizure. SGI changed significantly in favor of Group I (P=0.02). Subgroup analysis of subjects with baseline Ashworth scores >1 showed significant improvement in spasticity in Group I versus III (P=0.02). Conclusions: Group I showed significant improvement in SGI, and potential benefit on spasticity. The drug was well tolerated. Group II showed more adverse events and discontinuations. Sponsorship: The study was sponsored by Acorda Therapeutics, Inc.

Original languageEnglish
Pages (from-to)158-168
Number of pages11
JournalSpinal Cord
Volume45
Issue number2
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Spinal Cord Injuries
Placebos
Safety
Asthenia
Rehabilitation Centers
Vital Signs
Spasm
Sleep Initiation and Maintenance Disorders
Dizziness
Constipation
Double-Blind Method
Physical Examination
Headache
Electrocardiography
Urinary Bladder
Seizures
Outcome Assessment (Health Care)
Clinical Trials
Pain
Pharmaceutical Preparations

Keywords

  • 4-aminopyridine
  • Erectile function
  • Questionnaires
  • Randomized trial
  • Spasticity

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Cardenas, D. D., Ditunno, J., Graziani, V., Jackson, A. B., Lammertse, D., Potter, P., ... Blight, A. R. (2007). Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord, 45(2), 158-168. https://doi.org/10.1038/sj.sc.3101947

Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. / Cardenas, D. D.; Ditunno, J.; Graziani, V.; Jackson, A. B.; Lammertse, D.; Potter, P.; Sipski, M.; Cohen, R.; Blight, A. R.

In: Spinal Cord, Vol. 45, No. 2, 01.02.2007, p. 158-168.

Research output: Contribution to journalArticle

Cardenas, DD, Ditunno, J, Graziani, V, Jackson, AB, Lammertse, D, Potter, P, Sipski, M, Cohen, R & Blight, AR 2007, 'Phase 2 trial of sustained-release fampridine in chronic spinal cord injury', Spinal Cord, vol. 45, no. 2, pp. 158-168. https://doi.org/10.1038/sj.sc.3101947
Cardenas DD, Ditunno J, Graziani V, Jackson AB, Lammertse D, Potter P et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 2007 Feb 1;45(2):158-168. https://doi.org/10.1038/sj.sc.3101947
Cardenas, D. D. ; Ditunno, J. ; Graziani, V. ; Jackson, A. B. ; Lammertse, D. ; Potter, P. ; Sipski, M. ; Cohen, R. ; Blight, A. R. / Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. In: Spinal Cord. 2007 ; Vol. 45, No. 2. pp. 158-168.
@article{51a4e274d2a34130a5a71e3966b7c1d9,
title = "Phase 2 trial of sustained-release fampridine in chronic spinal cord injury",
abstract = "Study design: Double-blind, randomized, placebo-controlled, parallel-group clinical trial. Objective: Assess safety and efficacy of sustained-release fampridine in subjects with chronic spinal cord injury. Setting: A total of 11 academic rehabilitation research centers in the United States. Methods: A total of 91 subjects with motor-incomplete spinal cord injury (SCI), randomized to three arms: fampridine, sustained release, 25 mg b.i.d. (Group I), 40 mg b.i.d. (Group II), and placebo (Group III) for 8 weeks. Outcome measures: Patient diary questionnaire, Ashworth score, American Spinal Cord Injury Association International Standards, International Index of Erectile Function, bladder and bowel management questionnaires, and Clinician and Subject Global Impressions (Clinician Global Impression of change, Subject Global Impression (SGI)). Safety was evaluated from adverse events, physical examinations, vital signs, electrocardiograms, and laboratory tests. Results: In total, 78{\%} of the subjects completed the study. More (13/30) discontinued from Group II than Group I (4/30) and Group III (3/31). The most frequent adverse events across groups were hypertonia, generalized spasm, insomnia, dizziness, asthenia, pain, constipation, and headache. One subject in Group II experienced a seizure. SGI changed significantly in favor of Group I (P=0.02). Subgroup analysis of subjects with baseline Ashworth scores >1 showed significant improvement in spasticity in Group I versus III (P=0.02). Conclusions: Group I showed significant improvement in SGI, and potential benefit on spasticity. The drug was well tolerated. Group II showed more adverse events and discontinuations. Sponsorship: The study was sponsored by Acorda Therapeutics, Inc.",
keywords = "4-aminopyridine, Erectile function, Questionnaires, Randomized trial, Spasticity",
author = "Cardenas, {D. D.} and J. Ditunno and V. Graziani and Jackson, {A. B.} and D. Lammertse and P. Potter and M. Sipski and R. Cohen and Blight, {A. R.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1038/sj.sc.3101947",
language = "English",
volume = "45",
pages = "158--168",
journal = "Spinal Cord",
issn = "1362-4393",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Phase 2 trial of sustained-release fampridine in chronic spinal cord injury

AU - Cardenas, D. D.

AU - Ditunno, J.

AU - Graziani, V.

AU - Jackson, A. B.

AU - Lammertse, D.

AU - Potter, P.

AU - Sipski, M.

AU - Cohen, R.

AU - Blight, A. R.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Study design: Double-blind, randomized, placebo-controlled, parallel-group clinical trial. Objective: Assess safety and efficacy of sustained-release fampridine in subjects with chronic spinal cord injury. Setting: A total of 11 academic rehabilitation research centers in the United States. Methods: A total of 91 subjects with motor-incomplete spinal cord injury (SCI), randomized to three arms: fampridine, sustained release, 25 mg b.i.d. (Group I), 40 mg b.i.d. (Group II), and placebo (Group III) for 8 weeks. Outcome measures: Patient diary questionnaire, Ashworth score, American Spinal Cord Injury Association International Standards, International Index of Erectile Function, bladder and bowel management questionnaires, and Clinician and Subject Global Impressions (Clinician Global Impression of change, Subject Global Impression (SGI)). Safety was evaluated from adverse events, physical examinations, vital signs, electrocardiograms, and laboratory tests. Results: In total, 78% of the subjects completed the study. More (13/30) discontinued from Group II than Group I (4/30) and Group III (3/31). The most frequent adverse events across groups were hypertonia, generalized spasm, insomnia, dizziness, asthenia, pain, constipation, and headache. One subject in Group II experienced a seizure. SGI changed significantly in favor of Group I (P=0.02). Subgroup analysis of subjects with baseline Ashworth scores >1 showed significant improvement in spasticity in Group I versus III (P=0.02). Conclusions: Group I showed significant improvement in SGI, and potential benefit on spasticity. The drug was well tolerated. Group II showed more adverse events and discontinuations. Sponsorship: The study was sponsored by Acorda Therapeutics, Inc.

AB - Study design: Double-blind, randomized, placebo-controlled, parallel-group clinical trial. Objective: Assess safety and efficacy of sustained-release fampridine in subjects with chronic spinal cord injury. Setting: A total of 11 academic rehabilitation research centers in the United States. Methods: A total of 91 subjects with motor-incomplete spinal cord injury (SCI), randomized to three arms: fampridine, sustained release, 25 mg b.i.d. (Group I), 40 mg b.i.d. (Group II), and placebo (Group III) for 8 weeks. Outcome measures: Patient diary questionnaire, Ashworth score, American Spinal Cord Injury Association International Standards, International Index of Erectile Function, bladder and bowel management questionnaires, and Clinician and Subject Global Impressions (Clinician Global Impression of change, Subject Global Impression (SGI)). Safety was evaluated from adverse events, physical examinations, vital signs, electrocardiograms, and laboratory tests. Results: In total, 78% of the subjects completed the study. More (13/30) discontinued from Group II than Group I (4/30) and Group III (3/31). The most frequent adverse events across groups were hypertonia, generalized spasm, insomnia, dizziness, asthenia, pain, constipation, and headache. One subject in Group II experienced a seizure. SGI changed significantly in favor of Group I (P=0.02). Subgroup analysis of subjects with baseline Ashworth scores >1 showed significant improvement in spasticity in Group I versus III (P=0.02). Conclusions: Group I showed significant improvement in SGI, and potential benefit on spasticity. The drug was well tolerated. Group II showed more adverse events and discontinuations. Sponsorship: The study was sponsored by Acorda Therapeutics, Inc.

KW - 4-aminopyridine

KW - Erectile function

KW - Questionnaires

KW - Randomized trial

KW - Spasticity

UR - http://www.scopus.com/inward/record.url?scp=33846834028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846834028&partnerID=8YFLogxK

U2 - 10.1038/sj.sc.3101947

DO - 10.1038/sj.sc.3101947

M3 - Article

C2 - 16773037

AN - SCOPUS:33846834028

VL - 45

SP - 158

EP - 168

JO - Spinal Cord

JF - Spinal Cord

SN - 1362-4393

IS - 2

ER -